This booklet is for men who want to know more about a non-cancerous condition called an enlarged prostate. It explains the causes, symptoms, diagnosis and treatment of an enlarged prostate.
American Urological Association. 2003 (updated 2006). Guideline on the management of Benign Prostatic Hyperplasia (BPH).
De la Rosette J, Alivizatos G, Madersbacher S et al. Guidelines on benign prostatic hyperplasia. European Association of Urology 2008.
Electronic medicines compendium. Summary of product characteristics: Avodart.
Engeler DS, Schwab C, Neyer M et al. Bipolar versus monopolar TURP: a prospective controlled study at two urology centers. Prostate Cancer and Prostatic Diseases 2010;13: 285–291.
Hammadeh MY, Madaan S, Hines J, et al. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 2003; 61: 1166-1171
Kaplan ST. Update on the American Urological Association Guidelines for the Treatment of Benign Prostatic Hyperplasia. Reviews in Urology. 2006; 8(Supp 4): S10-S17.
Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int. 2008 Aug 5;102(5):536-44.
Martin DJ, Mulhall JP. Enlarging the scope of managing benign prostatic hyperplasia: addressing sexual function and quality of life. International Journal of Clinical Practice 2005; 59:579-90.
National Institute for Health and Clinical Excellence. Lower urinary tract symptoms. The management of lower urinary tract symptoms in men. 2010.
Neuhouser ML, Kristal AR, Penson DF. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. Urology 2004; 64: 201-11
Nickel JC, Barkin J, Koch C et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J. 2008; 2:16-21.
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on conservative treatment of non-neurogenic male LUTS. European Association of Urology 2010.
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology 2012.
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on treatment of non-neurogenic male LUTS. European Association of Urology 2011.
Parsons JK. Modifiable risk factors for benign prostatichyperplasia and lower urinary tract symptoms: new approaches to old problems. Journal of Urology. 2007; 178: 395-40
Parsons JK. Sarma AV. McVary K. Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. Journal of Urology 2009; 182 (Supp 6):S27-31
Pearson JD, Lei HH, Beaty TH et al. Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 2003; 61: 781–5
Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU International. 2008; 101 (supp 3): 17-21.
Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994; 152: 115–9
Sarma AV. Parsons JK. McVary K. Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know?. Journal of Urology 2009; 182 (supp 6): S32-7.
Schenk JM, Kristal AR, Arnold KB et al. Association of systematic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. American Journal of Epidemiology 2011: 173 (12): 1419-1428.
Tacklind J, Fink HA, MacDonald R et al. Finasteride for benign prostatic hyperplasia (review). The Cochrane Collaboration 2012.
Trueman P, Hood SC, Nayak USL et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999; 83: 410-415.
Tyson MD, Lerner LB. Safety of holmium laser enucleation of the prostate in anticoagulated patients. Journal of Endourology 2009;23(8):1343-6.
Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. Journal of Urology 2005; 173: 1256-1261.
Young JM, Muscatello DJ, Ward JF. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000; 85:1037-1048.